TABLE 2.
Test | Cutoffa | % Sensitivity | % Specificity | Predictive valueb at disease prevalence (%) |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50 |
20 |
3 |
1 |
0.1 |
0.001 |
||||||||||
PPV | NPV | PPV | NPV | PPV | NPV | PPV | NPV | PPV | NPV | PPV | NPV | ||||
CrAg-ELISA | 1.7 U/ml−1 | 97 | 100 | 100 | 97.09 | 100 | 99.26 | 100 | 99.91 | 100 | 99.97 | 100 | 100 | 100 | 100 |
NIE-ELISA | 119.04 U/ml−1 | 84 | 100 | 100 | 85.84 | 100 | 96.04 | 100 | 99.49 | 100 | 99.83 | 100 | 99.98 | 100 | 100 |
NIE-LIPS | 37.89 LU | 97.8 | 100 | 100 | 97.85 | 100 | 99.45 | 100 | 99.93 | 100 | 99.98 | 100 | 100 | 100 | 100 |
NIE-SsIR-LIPS | 1199 LU | 91.2 | 100 | 100 | 91.91 | 100 | 97.85 | 100 | 99.73 | 100 | 99.91 | 100 | 99.99 | 100 | 100 |
Cutoffs for NIE-LIPS, NIE-ELISA, NIE-SsIR-LIPS assays with corresponding sensitivity and specificity as calculated by ROC curve analysis. The cutoff for the CrAg-ELISA has been previously determined and was not determined by our analysis.
Calculated positive and negative predictive values (PPV and NPV, respectively) at a variety of prevalence levels based on the selected cutoff values.